-+ 0.00%
-+ 0.00%
-+ 0.00%

HUTCHMED INITIATES PHASE III STAGE OF THE ONGOING TRIAL OF THE COMBINATION OF SURUFATINIB AND CAMRELIZUMAB FOR TREATMENT-NAÏVE PANCREATIC DUCTAL ADENOCARCINOMA

路透·01/05/2026 00:00:03

登錄查看新聞詳情